Precigen, Inc.
PGENPrecigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari. Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
7wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
PRGN-2009 plus Pembrolizumab
Cervical Cancer
PRGN-2012 - Phase I; Dose Level 1
Recurrent Respiratory Papillomatosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PRGN-2009 plus Pembrolizumab | Phase 2 | Cervical Cancer | - | - |
PRGN-2012 - Phase I; Dose Level 1 | Phase 2 | Recurrent Respiratory Papillomatosis | - | - |